Viking Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 7, 2016

Details of these presentations are as follows:

•	Rodman & Renshaw 18th Annual Global Investment Conference
	Time/Date:	Tuesday, Sept. 13 at 12:05-12:30 PM ET
	Location:     ARIVA.DE Börsen-Geflüster Kurse Viking Therapeutics Inc 65,07 $ +0,22%	The Lotte New York Palace Hotel, New York City
	Room:	Holmes II (4th Floor)
•	Ladenburg Thalmann 2016 Healthcare Conference
	Time/Date:	Tuesday, Sept. 27 at 2:00-2:25 PM ET
	Location:	Sofitel New York, New York City
	Room:	Montmartre - Track 5

To access the live webcast of Viking's presentations, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcasts will be available on the Viking website following the conference.

About Viking Therapeutics, Inc. 
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Follow Viking on Twitter @Viking_VKTX.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-upcoming-investor-conferences-300323520.html

SOURCE Viking Therapeutics, Inc